HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage

被引:167
|
作者
Jung, KH
Chu, K
Jeong, SW
Han, SY
Lee, ST
Kim, JY
Kim, M
Roh, JK
机构
[1] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Neurol, Clin Res Inst,Stroke & Neural Stem Cell Lab, Seoul 110744, South Korea
[2] Seoul Natl Hosp, Dept Neurol, Seoul, South Korea
[3] Inje Univ, Ilsan Paik Hosp, Dept Neurol, Goyang, South Korea
关键词
HMG-CoA reductase inhibitors; intracerebral hemorrhage; brain edema; apoptosis; inflammation;
D O I
10.1161/01.STR.0000131270.45822.85
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Statins have neuroprotective effects on ischemic stroke. They modify the endothelial function, increase blood flow, and inhibit thrombus formation, which are independent of lipid-lowering effects. However, whether statins have a protective effect toward hemorrhagic stroke is yet unknown. To test this possibility, we attempted to determine the effect of atorvastatin on experimental intracerebral hemorrhage (ICH). Methods-ICH was induced using stereotaxic infusion of collagenase into the left basal ganglia in adult rats. Atorvastatin (1 mg/kg or 10 mg/kg) or phosphate-buffered saline was administered for 2 weeks. To monitor the sensorimotor deficits, limb placing and Rotorod tests were performed. Hematoma volume, brain water content, and hemispheric atrophy were analyzed. Immunohistochemical staining for myeloperoxidase (MPO), microglia (OX42), inducible nitric oxide synthase ( iNOS), or endothelial nitric oxide synthase (eNOS) was performed. Perihematomal cell death was determined by TUNEL staining. Results-The atorvastatin-treated ICH group showed better performance on Rotorod and limb placing tests when compared with the vehicle-treated group (P<0.01). The hematoma volumes between groups were not different, but the brain water content and hemispheric atrophy were reduced in the atorvastatin-treated ICH group. Atorvastatin reduced TUNEL-positive cells, iNOS expression, and MPO-positive or OX42-positive cells in the perihematomal regions in a dose-dependent manner, whereas it increased eNOS expression. Conclusion-The present study shows that atorvastatin reduces the perihematomal cell death via antiinflammation, which is associated with sensorimotor recovery after experimental ICH.
引用
收藏
页码:1744 / 1749
页数:6
相关论文
共 50 条
  • [1] HMG-CoA reductase inhibitor, atorvastatin, ameliorates sensorimotor dysfunctions in experimental intracerebral hemorrhage
    Chu, K
    Jung, KH
    Jeong, SW
    Song, YM
    Lee, ST
    Kim, M
    Roh, JK
    STROKE, 2004, 35 (01) : 246 - 246
  • [2] EFFECT OF FOOD ON THE BIOAVAILABILITY OF ATORVASTATIN, AN HMG-COA REDUCTASE INHIBITOR
    RADULOVIC, LL
    CILLA, DD
    POSVAR, EL
    SEDMAN, AJ
    WHITFIELD, LR
    JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (10): : 990 - 994
  • [3] Atorvastatin, a potent HMG-CoA reductase inhibitor, is not antipyretic in rats
    Kamerman, PR
    Modisa, BME
    Mphahlele, NR
    JOURNAL OF THERMAL BIOLOGY, 2004, 29 (7-8) : 431 - 435
  • [5] HMG-CoA reductase inhibitors are associated with an increased intracerebral hemorrhage volume
    Ricard, Genevieve
    Ntwari, Aime
    Boulanger, Jean-Martin
    STROKE, 2008, 39 (02) : 654 - 655
  • [6] Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase
    L. R. Whitfield
    R. H. Stern
    A. J. Sedman
    R. Abel
    D. M. Gibson
    European Journal of Drug Metabolism and Pharmacokinetics, 2000, 25 : 97 - 101
  • [7] DEVELOPMENTAL TOXICITY OF THE HMG-COA REDUCTASE INHIBITOR, ATORVASTATIN, IN RATS AND RABBITS
    DOSTAL, LA
    SCHARDEIN, JL
    ANDERSON, JA
    TERATOLOGY, 1994, 50 (06) : 387 - 394
  • [8] Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase
    Whitfield, LR
    Stern, RH
    Sedman, AJ
    Abel, R
    Gibson, DM
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2000, 25 (02) : 97 - 101
  • [9] Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
    BakkerArkema, RG
    Davidson, MH
    Goldstein, RJ
    Davignon, J
    Isaacsohn, JL
    Weiss, SR
    Keilson, LM
    Brown, WV
    Miller, VT
    Shurzinske, LJ
    Black, DM
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (02): : 128 - 133
  • [10] Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine
    Yang, BB
    Hounslow, NJ
    Sedman, AJ
    Forgue, ST
    JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (04): : 356 - 360